NCT00946686已完成1 期
A Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sandoz
- 入组人数
- 52
- 主要终点
- Bioequivalence based on AUC and Cmax
研究概览
简要总结
To demonstrate the relative bioavailability, parallel study Of Leflunomide 20 mg tablets under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
排除标准
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
研究组 & 干预措施
1
Experimental
Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
干预措施: Leflunomide 20 mg Tablets (Geneva Pharmaceutical) (Drug)
2
Active Comparator
Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
干预措施: Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.) (Drug)
结局指标
主要结局
Bioequivalence based on AUC and Cmax
时间窗: 11 days
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Leflunomide 20 mg Tablets, Non-FastingHealthyNCT00834405Teva Pharmaceuticals USA37
已完成
1 期
Leflunomide 20 mg Tablets Under Fasting ConditionsHealthyNCT00834418Teva Pharmaceuticals USA84
已完成
不适用
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed ConditionHealthyNCT01079052Ranbaxy Laboratories Limited24
已完成
1 期
Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)HyperlipidemiaNCT01353404Samyang Biopharmaceuticals Corporation24
尚未招募
不适用
Bioequivalence Study of 20 mg Leflunomide Film-coated Tablets in Healthy Thai VolunteersBioequivalence Study of 20 mg Leflunomide Film-coated Tablets in Healthy Thai VolunteersTCTR20180531002All Research Co., Ltd.38